Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Free Radic Biol Med. 2016 Nov 9;102:217–228. doi: 10.1016/j.freeradbiomed.2016.11.008

Fig. 9.

Fig. 9

pp60Src inhibits DDAH II activity through Y207. HEK293 cells were transduced AdY527FSrc or AdGFP along with wild-type DDAH II for 48 h. Over-expression of Ad527FSrc increased pY207 DDAH II levels as measured by Western blot analysis using a phospho-antibody that recognizes pY207 in DDAH II (A). HEK293 were transduced with (AdY527FSrc) or AdGFP and transfected with either wildtype (WT) DDAH II or a DDAH II mutant in which Y207 was replaced by phenlyalanine (Y207FDDAH II). Immunoblot analysis identified a similar increase in DDAH II levels in WT DDAH II or Y207F DDAH II transfected cells (B). HEK293 cells transduced with AdY527FSrc exhibited a significant increase in pp60Src expression (C). The over-expression of AdY527FSrc decreased DDAH II activity (D) and increased ADMA levels (E) in cells expressing WT DDAH II. However, AdY527FSrc did decrease DDAH activity (D) or increase ADMA levels (E) levels in cells expressing the Y207F DDAH II mutant. Values are mean± SEM, n=4–6, *P< 0.05 vs. WT DDAH II alone.